SCHEMBL15919672

SCHEMBL15919672

O=C(NNCl)c1cc(-c2ccc(-c3ccc(CC(=O)N4CCOCC4)cc3)cc2)nc2ccncc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
KDM4E B2RXH2 3/20 0.46
LMNA P02545 3/20 0.46
NPC1 O15118 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NPSR1 Q6W5P4 1/20 0.43
GPR55 Q9Y2T6 1/20 0.43
ALDH1A1 P00352 3/20 0.43
SYK P43405 2/20 0.43
XBP1 P17861 1/20 0.43
KCNH2 Q12809 1/20 0.43
TSHR P16473 2/20 0.43
HDAC1 Q13547 1/20 0.42
PRKAB2 O43741 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15904995 0.90 MAPT (0.50) MAPTKDM4ELMNANPC1CYP3A4
Hydrochloric Acid SCHEMBL15905149 0.90 MAPT (0.49) MAPTKDM4ELMNANPC1CYP3A4
SCHEMBL15919452 0.87 L3MBTL1 (0.49) MAPTKDM4ELMNANPC1MEN1
SCHEMBL15919659 0.86 KDM4E (0.44) MAPTKDM4ELMNANPC1CYP3A4
SCHEMBL15919356 0.85 ALDH1A1 (0.49) MAPTKDM4ELMNANPC1CYP3A4
SCHEMBL15919600 0.79 KCNH2 (0.56) MAPTKDM4ELMNANPC1CYP3A4
SCHEMBL15919743 0.78 L3MBTL1 (0.51) MAPTKDM4ELMNANPC1NPSR1
SCHEMBL15905383 0.78 MAPT (0.57) MAPTKDM4ELMNACYP3A4CYP2C9
Hydrochloric Acid SCHEMBL15905480 0.77 L3MBTL1 (0.51) MAPTKDM4ELMNANPC1NPSR1
SCHEMBL15919473 0.76 DHODH (0.42) MAPTKDM4ELMNACYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO MAPT 2507/4885KDM4E 3322/4885LMNA 4266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.